Trajentamet

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ixtrih issa

Ingredjent attiv:

Linagliptin 2.5mg;  ; Metformin hydrochloride 850mg

Disponibbli minn:

Boehringer Ingelheim (NZ) Ltd

INN (Isem Internazzjonali):

Linagliptin 2.5 mg

Dożaġġ:

2.5 mg/850 mg

Għamla farmaċewtika:

Film coated tablet

Kompożizzjoni:

Active: Linagliptin 2.5mg   Metformin hydrochloride 850mg Excipient: Arginine Colloidal silicon dioxide Copovidone Hypromellose Iron oxide red Iron oxide yellow Magnesium stearate Maize starch Propylene glycol Purified talc Purified water Titanium dioxide

Tip ta 'preskrizzjoni:

Prescription

Indikazzjonijiet terapewtiċi:

TRAJENTAMET is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. TRAJENTAMET is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on metformin alone or those already being treated and well controlled with the free combination of linagliptin and metformin. TRAJENTAMET is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. TRAJENTAMET is indicated in combination with an SGLT2 inhibitor (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an SGLT2 inhibitor. TRAJENTAMET is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 14 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 28 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 30 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 56 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 60 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 90 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 98 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 100 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Blister pack, PVC/PCTFE/Alu. blister sheet in printed carton - 120 tablets - 36 months from date of manufacture stored at or below 25°C protect from moisture - Bottle, plastic, HDPE with CRC cap, induction seal and desiccant capsule in printed carton - starter pack - 14 tablets - 36 months from date of manufacture stored at or below 30°C protect from moisture - Bottle, plastic, HDPE with CRC cap, induction seal and desiccant capsule in printed carton - 60 tablets - 36 months from date of manufacture stored at or below 30°C protect from moisture - Bottle, plastic, HDPE with CRC cap, induction seal and desiccant capsule in printed carton - 180 tablets - 36 months from date of manufacture stored at or below 30°C protect from moisture

Data ta 'l-awtorizzazzjoni:

2014-12-01

Ara l-istorja tad-dokumenti